Propensity score analysis on the effect of immunosuppressive therapy
| Control Group | Treatment Group | P | |
|---|---|---|---|
| n | 39 | 39 | |
| Patients per era (era 1, 2, 3, respectively) | 11, 20, 8 | 5, 25, 9 | >0.1 |
| At presentation | |||
| female gender (%) | 18 | 26 | >0.1 |
| age | 50 ± 15 | 49 ± 13 | >0.1 |
| CrCl (ml/min per 1.73 m2) | 76 ± 26 | 77 ± 23 | >0.1 |
| MAP (mmHg) | 100 ± 12 | 101 ± 12 | >0.1 |
| proteinuria (g/d) | |||
| initial | 9.5 (6.4 to 11.7) | 6.9 (5.1 to 10.5) | >0.1 |
| peak | 12.2 (9.1 to 16.8) | 11.5 (10.0 to 15.6) | >0.1 |
| number of antihypertensive drugs | 0 (0 to 1) | 0 (0 to 1) | >0.1 |
| Therapy during follow-up | |||
| number of antihypertensive drugs | 0.7 (0.3 to 1.2) | 0.7 (0.1 to 1.3) | >0.1 |
| RAS blockade (%) | 41 | 39 | >0.1 |
| duration (% of patient follow-up) | 43 (7 to 74) | 45 (28 to 85) | >0.1 |
| immunosuppression | |||
| cyclophosphamide/chlorambucil (n) | – | 32/1a | By design |
| cyclosporine (n) | – | 12a | |
| corticosteroids (n) | – | 25 | |
| Clinical follow-up | |||
| MAP (mmHg) | 102 ± 9 | 101 ± 9 | >0.1 |
| proteinuria | |||
| change from peak to last (g/d) | −4.7 (−9.8 to −1.6) | −9.1 (−14.4 to −5.2) | 0.01 |
| absence of remission (%) | 56 | 21 | 0.01 |
| slope (ml/min per 1.73 m2 per year) | −6.1 ± 11.0 | −3.6 ± 6. 8 | >0.1 |
| renal survival | See Figure 3 |
Values are expressed as mean ± SD or median (interquartile range). CrCl, Creatinine clearance; MAP, mean arterial pressure.
↵a All patients received either cytotoxic or cyclosporine treatment (six patients received both during follow-up).